<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706615</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000599060</org_study_id>
    <secondary_id>UCLA-07-05-056</secondary_id>
    <nct_id>NCT00706615</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer</brief_title>
  <official_title>A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in&#xD;
      treating women with previously treated metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Characterize the safety profile of Ad-sig-hMUC-1/ecdCD40L vaccine in women with&#xD;
           metastatic breast cancer.&#xD;
&#xD;
        -  Identify a tolerable, immunologically active dose level of this vaccine in these&#xD;
           patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the immune function in these patients before and after treatment with this&#xD;
           vaccine.&#xD;
&#xD;
      OUTLINE: Patients receive MUC-1 vector vaccine subcutaneously on day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed monthly for 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no accrual&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile of the Ad-sig-hMUC-1/ecdCD40L vector vaccine</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of a tolerable, immunologically active dose level</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess efficacy based on serum MUC-1 level</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad-sig-hMUC-1/ecdCD40L vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women over the age of 18 with metastatic or non-measureable adenocarcinoma of the&#xD;
             breast with marrow involvement.&#xD;
&#xD;
          -  Elevated serum MUC-1 levels, as measured by CA 15-3 or CA 27-29&#xD;
&#xD;
          -  Stable disease (defined as fluctuation of &lt;50U in CA15-3 or CA27-29 value) for at&#xD;
             least 3 months while either on no breast-cancer therapy or while on current therapy&#xD;
             (Tamoxifen, fulvestrant, exemestane, letrozole, anastrozole, bisphosphonates or&#xD;
             trastuzumab chemotherapy is not allowed)&#xD;
&#xD;
          -  ability to understand the risks, benefits, and procedures and provide written informed&#xD;
             consent.&#xD;
&#xD;
          -  less than 28 days prior to enrollment since last surgery and/or radiation therapy.&#xD;
&#xD;
          -  performance status &lt;=2 on the ECOG performance scale and life expectancy of greater&#xD;
             than 12 months&#xD;
&#xD;
          -  NYHA cardiac function Class I or Class II and normal baseline ECG. If ECG is abnormal,&#xD;
             patient must have an echocardiogram showing a left ventricular ejection fraction&#xD;
             greater than the lower limits of normal.&#xD;
&#xD;
          -  patients who do not have radiographically assessable locally recurrent or metastatic&#xD;
             disease are eligible if they 1) had radiographic or biopsy proven locally recurrent or&#xD;
             metastatic breast cancer in the past and 2) currently (at study entry) have an&#xD;
             elevated serum MUC-1 level (as measured by CA 15-3 or CA 27-29).&#xD;
&#xD;
          -  Acceptable pulmonary function. if questionable, a pulmonary function test will be&#xD;
             performed.&#xD;
&#xD;
          -  negative serology for hepatitis B, C and HIV.&#xD;
&#xD;
          -  red cell mean corpuscular volume &gt;- 80 cu. mm, hemoglobin &gt;- 8g/dl, platelet count &gt;-&#xD;
             100,000/dl: AST, ALT, LDH &lt;-2 times the Upper limit of normal&#xD;
&#xD;
          -  Serum creatinine &lt; 1.6 mg/dL&#xD;
&#xD;
          -  for women with child bearing potential, Negative urine pregnancy test within 7 days of&#xD;
             registration and willingness to use an approved contraceptive method while&#xD;
             participating in this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of bronchospasm or asthma requiring inhaled or oral steroid treatment&#xD;
&#xD;
          -  Normal MUC-1 (CA 15-3 or CA 27-29)&#xD;
&#xD;
          -  treatment with steroid or other immunosuppressive medication (for any condition )&#xD;
             within 30 days of trial registration.&#xD;
&#xD;
          -  history of any autoimmune disease (e.g., lupus, rheumatoid arthritis, or psoriasis)&#xD;
&#xD;
          -  uncontrolled diabetes mellitus&#xD;
&#xD;
          -  unable or unwilling to undergo repeated clinical evaluations and other diagnostic&#xD;
             procedures or unable to sign an informed consent.&#xD;
&#xD;
          -  history of other malignancies, except squamous cell or basal cell carcinoma of the&#xD;
             skin or cervical carcinoma in situ.&#xD;
&#xD;
          -  Concurrent systemic chemotherapy (tamoxifen, aromatase inhibitors, fulvestrant,&#xD;
             trastuzumab and biophosphonates are allowed if started more than 3 months prior to&#xD;
             trial registration with evidence of stable disease as defined above. Chemotherapy must&#xD;
             have stopped 3 months prior to enrolling in this trial).&#xD;
&#xD;
          -  history of ornithine transcarbamylase deficiency&#xD;
&#xD;
          -  any acute or chronic viral, bacterial, or fungal infection requiring specific therapy,&#xD;
             unless acute therapy was completed within the past 14 days&#xD;
&#xD;
          -  No underlying conditions that would contraindicate therapy with study treatment ( or&#xD;
             allergies to reagents used in this study)&#xD;
&#xD;
          -  history of organ transplant or allogeneic bone marrow transplant&#xD;
&#xD;
          -  life threatening or organ-threatening disease expected to require conventional therapy&#xD;
             within 4 months.&#xD;
&#xD;
          -  pregnant or nursing females.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Hurvitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

